Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 2 results out of 2
Data Insights
Risk adjusted net present value: What is the current valuation of Merck's MK-8527?
MK-8527 is a small molecule commercialized by Merck, with a leading Phase II program in Human Immunodeficiency Virus (HIV) Infections...
Data Insights
MK-8527 by Merck for Human Immunodeficiency Virus (HIV) Infections (AIDS): Likelihood of Approval
MK-8527 is under clinical development by Merck and currently in Phase II for Human Immunodeficiency Virus (HIV) Infections (AIDS). According...